不同剂量瑞舒伐他汀联合曲美他嗪治疗不稳定型心绞痛临床效果及对心功能的影响

Clinical Efficacy and Effects on Cardiac Function of Different Doses of Rosuvastatin Combined with Trimetazidine in Treatment of Patients with Unstable Angina Pectoris

目的 探讨不同剂量瑞舒伐他汀联合曲美他嗪治疗不稳定型心绞痛患者的临床效果及对心功能的影响。方法 对2015年5月—2017年12月就诊的不稳定型心绞痛患者118例的临床资料进行回顾性分析。根据瑞舒伐他汀剂量分为低剂量组56例和高剂量组62例。低剂量组每晚予以10mg瑞舒伐他汀口服,高剂量组每晚予以20mg瑞舒伐他汀口服,均治疗3个月。治疗结束后比较2组血清同型半胱氨酸(Hcy)、C-反应蛋白(CRP)和血浆内皮素(ET)水平及心功能和临床疗效,并记录2组不良反应的发生情况。结果 2组治疗后Hcy、CRP和ET水平均较治疗前下降,且高剂量组低于低剂量组(P<0.05,P<0.01)。2组患者治疗后心功能均较治疗前改善,高剂量组改善程度优于低剂量组(P<0.05,P<0.01)。高剂量组总有效率高于低剂量组(P<0.05)。2组不良反应发生率比较差异无统计学意义(P>0.05)。结论 高剂量瑞舒伐他汀联合曲美他嗪治疗不稳定型心绞痛患者更有利于改善心功能和提高其临床疗效,且具有一定的安全性。

Objective To investigate clinical efficacy and effects on cardiac function of different doses of Rosuvastatin combined with Trimetazidine in treatment of patients with unstable angina pectoris. Methods Clinical data of118 patients with unstable angina pectoris admitted during May2015 and December2017 was retrospectively analyzed, and the patients were divided into low-dose group ( n =56) and high-dose group ( n =62) according to Rosuvastatain doses. Low-dose group was treated with10 mg Rosuvastatin orally every night, while high-dose group was treated with20 mg Rosuvastatin orally every night. Patients in both groups were treated for 3 months. After treatment, levels of serum homocysteine (Hcy), c-reactive protein (CRP) and plasma endothelin (ET), cardiac function and clinical efficacy were compared, and incidence rate of adverse reactions were recorded in two groups. Results After treatment, levels of Hcy, CRP and ET were significantly lower than those before treatment in two groups, but the levels in high-dose group were significantly lower than those in low-dose group ( P <0.05, P <0.01);conditions of cardiac function were significantly improved after treatment than those before treatment in two groups, and the improved condition in high-dose group was significantly better than that in low-dose group ( P <0.05, P <0.01). The total effective rate in high-dose group was significantly higher than that in low-dose group ( P <0.05). There was no significant difference in incidence rate of adverse reactions between two groups ( P >0.05). Conclusion High-dose Rosuvastatin combined with Trimetazidine in treatment of patients with unstable angina pectoris is more beneficial to improve cardiac function and clinical efficacy with a certain safety.